Sep 01, 2026
Alumis (ALMS) Stock Crashes Over 50% Following Lupus Trial Disappointment
Alumis (ALMS) stock plummeted 56% after Phase 2b lupus trial failure. IFNGS-high subgroup showed promise. Psoriasis NDA filing still planned for Q4 2026.
The post Alumis (ALMS) Stock Crashes Over 50% Following Lupus Trial Disappointment appeared first on Blockonomi.
Source: Blockonomi →Related News
- 42 minutes ago
Nasdaq Futures Rise as Tech Optimism and Middle East Oil News Drive Markets
- 43 minutes ago
Nvidia (NVDA) Stock Gains 1.6% as CEO Jensen Huang Pushes Back Against AI Regula...
- 44 minutes ago
Tesla (TSLA) Stock Gains Momentum Following First-Ever Fitch BBB Rating
- 44 minutes ago
Micron (MU) Stock Slides as Taiwan Plant Faces Strike Threat Over Profit-Sharing...
- 1 hour ago
SpaceX (SPCX) Stock: Morgan Stanley Highlights Power Infrastructure as Key AI Di...